Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Common Equity (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Common Equity for 16 consecutive years, with $368.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 47.51% to $368.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $368.0 million, a 47.51% decrease, with the full-year FY2025 number at $368.0 million, down 47.51% from a year prior.
  • Common Equity was $368.0 million for Q4 2025 at Myriad Genetics, down from $372.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $968.5 million in Q3 2021 to a low of $368.0 million in Q4 2025.
  • A 5-year average of $760.9 million and a median of $771.6 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: increased 9.85% in 2021, then crashed 49.05% in 2025.
  • Myriad Genetics' Common Equity stood at $967.8 million in 2021, then fell by 8.47% to $885.8 million in 2022, then decreased by 11.58% to $783.2 million in 2023, then decreased by 10.48% to $701.1 million in 2024, then plummeted by 47.51% to $368.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Common Equity are $368.0 million (Q4 2025), $372.8 million (Q3 2025), and $388.1 million (Q2 2025).